ArticleAdvanced healthcare materials2026
Cell Surface Thiol Engineering Mechanoregulates Myogenic Differentiation via the FAK-PI3K-AKT Axis.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Silk Fibroin Peptides Promote Extracellular Matrix Homeostasis in Photoaging via Modulation of the ITGB1/FAK-TGF-β/Smad Signaling Axis.Molecules (Basel, Switzerland) · 2026Article
- ITGA1 promotes osteogenic differentiation of human periodontal ligament stem cells via FAK-mediated PI3K-Akt activation.Stem cell research & therapy · 2026Article
- Modulating cell surface chemistry through mild reduction reinforces extracellular-to-intracellular transmission forces and mechano-signaling.Materials today. Bio · 2026Article
- Cell Surface Thiol Engineering Mechanoregulates Myogenic Differentiation via the FAK-PI3K-AKT Axis.Advanced healthcare materials · 2026Article
- A Monolithic 3D-Printed Platform for Functional Maturation and In Situ Contractility Assessment of 3D Skeletal Muscle.Biomaterials research · 2026Article
- Cell surface engineering for inhibition of breast cancer cell motility through modulation of mechanotransduction and focal adhesion dynamics.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Skeletal muscle regeneration is essential in conditions like muscle injury and muscular dystrophy, primarily relying on the activation and differentiation of myogenic progenitors. This study explores the role of redox-modulated surface thiol modification in myogenesis, using tris(2-carboxyethyl)phosphine hydrochloride (TCEP) to reduce disulfide bonds and generate free thiol groups on the cell surface. The findings show that TCEP treatment significantly increases cell surface thiols, activating the focal adhesion kinase (FAK)-phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling pathway, and promoting cell spreading, adhesion, and actin cytoskeleton remodeling. This biochemical modulation upregulates myogenic and fusion-related markers, facilitating multinucleated myotube formation. Biophysical analysis using traction force microscopy (TFM), intracellular force microscopy (IFM), and monolayer stress microscopy (MSM) demonstrates that TCEP-treated cells, particularly at muscle-relevant stiffness (20 kPa), exhibit increased traction, intracellular, and monolayer stresses compared to untreated cells. These results suggest that redox-modulated surface thiol modification, combined with specific stiffness conditions, enhances myogenic differentiation and myotube maturation through biomechanical signaling. This proof-of-concept study advances the understanding of how redox-modulated surface engineering and substrate stiffness regulate myogenesis, offering novel therapeutic strategies for muscle regeneration and optimization of stem cell-based therapies for muscle tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.